Post hoc analysis of FLAME (3362 patients with moderate-to-severe COPD): stopping LAMA was associated with a transient rise in moderate-to-severe exacerbations in the first quarter (rate ratio up to 2.2), and stopping ICS with an early rise in severe exacerbations.
Secondary analysisn = 3,362
Mathioudakis et al. Disproportionate increase in COPD exacerbation risk for 3 months after discontinuing LAMA or ICS: insights from the FLAME trial